Theravance Advances Respiratory Program via Glaxo Partnership
This article was originally published in Start Up
Executive Summary
The goal of the deal between Glaxo and Theravance is to pool programs in order to develop a best-in-class long-acting beta agonist. That Glaxo is contributing its most advanced compounds to the program and has agreed to pay royalties even on LABAs it may develop separately validates Theravance's technology. But it also shows how Glaxo is weighing the value of external vs. internal R&D.
You may also be interested in...
GSK's Risk-Sharing Deals to Compete with In-House R&D
Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.
GSK's Risk-Sharing Deals to Compete with In-House R&D
Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.
Theravance/Astellas: Quality Deal but without the Brand Name
Branding works--in packaged goods and among investors. That's why, rather than taking Theravance's rich marketing deal with the Japanese company Astellas for the antibiotic telavancin -- rich in comparison to the best licensing deals signed in the segment -- as a net positive for the company, shareholders seemed disappointed.